Adaptive Biotechnologies Corp (ADPT) company profile
Close on Nov 17, 2026Market cap $4.55BP/E –Yield –
About Adaptive Biotechnologies
Biological Products, (No Diagnostic Substances), SIC 2836
Adaptive Biotechnologies Corporation operates an immune medicine platform that decodes the adaptive immune system to diagnose and treat diseases. The company is organized into two primary segments: the Minimal Residual Disease (MRD) business and the Immune Medicine (IM) business. In its MRD division, the company provides the clonoSEQ diagnostic test to measure residual disease burden in lymphoid malignancies, serving clinicians in healthcare settings and biopharmaceutical companies conducting clinical drug development trials. The IM business sequences, maps, and characterizes immune receptors, offering solutions such as immunosequencing services, data licensing, predictive models, and target discovery services to academic and biopharmaceutical partners.
The company operates primarily within the United States while holding international certification in Europe and licensing its technology to partner laboratories across Europe, Australia, and Japan. Its clinical testing workflows are integrated across multiple electronic medical record networks, including Epic and Flatiron Health. The provided text does not state the company's headquarters location.
Summary of the business section of Adaptive Biotechnologies's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Adaptive Biotechnologies Corp
- Founded
- 2009
- Headquarters
- Seattle, WA
- Address
- 1165 Eastlake Ave E 98109
- Phone
- (206) 659-0067
- Website
- www.adaptivebiotech.com
- Employees
- 624, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Washington
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, Seattle, Washington
Stock & identifiers
- Ticker
- ADPT
- Exchange
- Nasdaq
- IPO date
- Jun 27, 2019
- Shares outstanding
- 160M, Jul 31, 2026
- Public float
- $1.39B, Jun 30, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 1478320
- CUSIP
- 00650F109
- ISIN
- US00650F1093
- FIGI
- BBG001J2PFF5
- Share class FIGI
- BBG001V0GG18
- LEI
- 549300ZTF7OT1FW66Q96
- EIN
- 27-0907024
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Chad M. Robins | CEO and Chairman, Director | 2,930,518 |
| Julie Rubinstein | President and COO | 377,802 |
| Susan Bobulsky | Chief Commercial Officer, MRD | 387,475 |
| Francis Lo | Chief People Officer | 223,367 |
| Harlan S. Robins | Chief Scientific Officer | 2,104,458 |
| Sharon Benzeno | Chief Commercial Ofc Imm Med | 299,532 |
| Kyle Piskel | Chief Financial Officer | 256,725 |
| Katey Einterz Owen | Director | 66,100 |
| Robert Hershberg | Director | 77,347 |
| Peter M. Neupert | Director | 255,315 |
| Michelle Renee Griffin | Director | 15,625 |
| Michael J. Pellini | Director | 69,690 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $9.08M | $39.60M | $4.99M | $27 | $125 |
| FY2024 | $4.97M | $8.35M | $2.39M | $10 | $93 |
| FY2023 | $8.90M | $2.75M | $4.26M | $8 | $94 |
| FY2022 | $8.85M | -$1.14M | $4.32M | $13 | $90 |
| FY2021 | $8.75M | -$6.18M | $5.87M | $47 | $100 |
| FY2020 | $7.13M | $24.87M | $4.13M | $198 | $126 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| Chad Robins Chief Executive Officer and Chairman | $698.26K | $7.68M | – | $703.38K | $4.95K | $9.08M | +83% |
| Kyle Piskel Chief Financial Officer | $399.95K | $2.70M | – | $203.30K | $4.98K | $3.31M | +157% |
| Susan Bobulsky Chief Commercial Officer, MRD | $435.75K | $1.88M | $997.33K | $226.01K | $4.48K | $3.55M | +108% |
| Harlan Robins Chief Scientific Officer | $558.65K | $7.68M | – | $270.82K | $5.00K | $8.51M | +87% |
| Julie Rubinstein President and Chief Operating Officer | $542.38K | $3.78M | – | $273.18K | $4.93K | $4.60M | +74% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Jun 27, 2019
- Offer price
- $20.00
- Securities offered
- 15,000,000
- Gross proceeds
- $300.00M
- Exchange
- Nasdaq
- First trading day
- Jun 27, 2019
- First-day close
- $40.30+101.5%
- Lock-up ends (est.)
- Dec 24, 2019
“The initial public offering price of our common stock is $20.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 624 full-time employees of which 94 hold medical or doctoral degrees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jul 3, 2023 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Jun 27, 2019 | IPO | Initial public offering priced (424B4 prospectus) |
| Jun 26, 2019 | Listing | Registration of securities on an exchange (Form 8-A) |
| Jun 2, 2011 | Name change | Name changed from Adaptive TCR Corp to Adaptive Biotechnologies Corp |
See a number that looks wrong?